CBD Coffee Pioneer Ready to Shake Up the Category with $2 Million Series A Round
FRAMINGHAM, Mass. – Flower Power Coffee Company is poised to seize leadership in the explosive CBD coffee category, announcing plans to raise USD $2M in Series A Capital for expanding sales operations, marketing and channel support.
According to Nielsen, as reported in Hemp Industry Daily December 14, 2020, “With consumer interest in hemp-derived CBD showing no signs of waning, companies are looking to one particular consumer product good as a conduit for cannabidiol: coffee.” As America’s most popular daily beverage, coffee represents the best opportunity to introduce CBD to existing daily consumer behavior.
Flower Power has a patent-pending process that guarantees 25 mg of CBD in every brewed cup. Other CBD coffee brands lose most of the CBD during brewing. Independent Lab tests show little or no CBD in their brewed cups. Flower Power is the only coffee tested that delivers on its claims for CBD content, leading the charge for truth in labeling in a category where competitive products fall significantly short.
Just as importantly, Flower Power is committed to a premium quality coffee experience. Where others put 8-10 grams of standard ground coffee in each pod, Flower power adds 13 grams of ultra-premium, artisan-roasted high-altitude beans, delivering a richer more satisfying flavor on par with the very best gourmet coffees.
“When developing our products, we set out to establish new standards for quality, taste, accuracy and truth in labeling,” explained Chuck Siegel, Flower Power’s CEO. “We’ve taken every measure to ensure premium quality, from the selection of our roasting partners to our rigorous quality control and lab testing,” Siegel continued, “and we’re set up for mass market scale.”
(This information is primarily sourced from Flower Power Coffee Company. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).
Reunion Neuroscience to be Acquired by MPM BioImpact in $13.1 Million All-Cash Deal
LOS ANGELES-- Reunion Neuroscience Inc. a clinical-stage biopharmaceutical company specializing in innovative therapies for underserved mental health conditions, has announced a definitive arrangement agreement with MPM BioImpact, a leading biotechnology investment firm. Under the agreement, ...
California’s Regulated Cannabis Market Sees Decline in Sales and Tax Revenue in Q1 2023
LOS ANGELES-- California's hopes of increased consumer participation in the regulated cannabis market did not translate into a boost in licensed retail sales or state tax revenue during the first quarter of 2023. According to ...
C21 Investments Repays $30 Million Debt to CEO Sonny Newman
LOS ANGELES-- C21 Investments Inc., a vertically integrated cannabis company, announced today the successful completion of the full repayment of its $30 million senior secured note owed to Sonny Newman, the Company's President and Chief ...